Elicera Therapeutics AB - Asset Resilience Ratio

Latest as of December 2022: 0.00%

Elicera Therapeutics AB (ELIC) has an Asset Resilience Ratio of 0.00% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ELIC working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

Skr17.00

≈ $1.83 USD Cash + Short-term Investments

Total Assets

Skr46.31 Million

≈ $4.98 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how Elicera Therapeutics AB's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Elicera Therapeutics AB assets under control.

Liquid Assets Composition Over Time

This chart breaks down Elicera Therapeutics AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Elicera Therapeutics AB debt and liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Skr0.00	0%
Short-term Investments	Skr17.00	0.0%
Total Liquid Assets	Skr17.00	0.00%

Asset Resilience Insights

Limited Liquidity: Elicera Therapeutics AB maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Elicera Therapeutics AB Industry Peers by Asset Resilience Ratio

Compare Elicera Therapeutics AB's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Elicera Therapeutics AB (2022–2022)

The table below shows the annual Asset Resilience Ratio data for Elicera Therapeutics AB.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	0.00%	Skr17.00 ≈ $1.83	Skr46.31 Million ≈ $4.98 Million	--

pp = percentage points

About Elicera Therapeutics AB

ST:ELIC Sweden Biotechnology

Market Cap

$14.55 Million

Skr135.17 Million SEK

Market Cap Rank

#26163 Global

#538 in Sweden

Share Price

Skr2.79

Change (1 day)

-0.71%

52-Week Range

Skr2.30 - Skr7.90

All Time High

Skr8.56